Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced it has ...
JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing ...
CRISPR functions as a programmable genetic memory system derived from bacterial immune defenses against viral infections. Guide RNA allows for rapid multiplexed targeting compared to older ...
The MarketWatch News Department was not involved in the creation of this content. License agreement provides Jumpcode Genomics access to CRISPR gene editing technology to enhance next-generation ...
CRISPR gene editing has revolutionized the field of molecular biology, offering precise, efficient, and versatile tools for genome modification. The technology has rapidly evolved beyond the original ...
A compact Cas12f nuclease shows high editing efficiency in human cells, with structural insights enabling an engineered variant potentially suited for future AAV‑compatible delivery.
Scientists have worked tirelessly to develop ever more precise and efficient CRISPR-Cas systems to reach the ultimate goal: safe and effective CRISPR-Cas-based medical treatments. Over the years, ...
There may be a new entrant soon in the competitive race of gene editing: San Diego’s Isis Pharmaceuticals has teamed up with University of California, San Diego to produce research that demonstrates a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results